Marchex Reports Q4 2025 Earnings Miss with Significant Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MCHX?
Source: seekingalpha
- Earnings Report Disappointment: Marchex's Q4 2025 non-GAAP EPS of -$0.04 misses expectations by $0.03, indicating ongoing pressure on the company's profitability.
- Revenue Decline: The fourth quarter revenue of $10.8 million represents a 9.4% year-over-year decrease, falling short of expectations and reflecting weakened market demand and intensified competition.
- Adjusted EBITDA Loss: The adjusted EBITDA loss of $1.2 million for Q4 2025 is significantly higher than the $0.4 million loss reported in Q4 2024, highlighting challenges in cost management.
- Impact of Reorganization Costs: The 2025 adjusted EBITDA loss includes $1.6 million in reorganization and historical acquisition-related costs, but excluding these would result in a $0.4 million gain, suggesting potential profitability in core operations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MCHX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MCHX
About MCHX
Marchex, Inc. provides conversation intelligence platform. The Company harnesses the power of artificial intelligence (AI) and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics. The Company’s product offerings include Marketing Edge, Sonar Business Text Messaging, Marchex Platform Services, Spotlight, Engage, Call Summary and Sentiment Suite, and AI for Industry Solution. Marketing Edge leverages conversational intelligence with generative AI to form a comprehensive marketing attribution and conversation data solution. Sonar Business Text Messaging is an AI empowered, intelligent workflow enabled mobile messaging solution that enables operations, sales and marketing teams to communicate personally with field staff, prospects and customers. Marchex Platform Services a robust application programming interface (API) for conversation intelligence.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Marchex Q4 2025 Earnings Call Insights
- Revenue Shift: For Q4 2025, Marchex reported revenue of $10.8 million, down from $11.5 million in Q3, primarily due to migration activities; however, new sales and upsells from existing customers positively impacted the company.
- Technology Migration: The company anticipates completing the migration of approximately 1,000 customers by the end of 2025, positioning itself to focus on accelerating revenue growth and margin expansion, with a projected 10% revenue growth in 2026.
- AI-Driven Product Innovation: Marchex is leveraging AI to introduce new bundled solutions, with initial positive adoption indications in the Home Services and Auto Services sectors, highlighting the company's strategic advantage in customer acquisition and retention.
- Acquisition Outlook: The Archenia acquisition is expected to close by June 2026, with combined quarterly revenues potentially reaching $15 million and annual growth rates projected between 15% and 20%, indicating strong market potential.
See More
Marchex Reports Q4 2025 Earnings Miss with Significant Losses
- Earnings Report Disappointment: Marchex's Q4 2025 non-GAAP EPS of -$0.04 misses expectations by $0.03, indicating ongoing pressure on the company's profitability.
- Revenue Decline: The fourth quarter revenue of $10.8 million represents a 9.4% year-over-year decrease, falling short of expectations and reflecting weakened market demand and intensified competition.
- Adjusted EBITDA Loss: The adjusted EBITDA loss of $1.2 million for Q4 2025 is significantly higher than the $0.4 million loss reported in Q4 2024, highlighting challenges in cost management.
- Impact of Reorganization Costs: The 2025 adjusted EBITDA loss includes $1.6 million in reorganization and historical acquisition-related costs, but excluding these would result in a $0.4 million gain, suggesting potential profitability in core operations.
See More
Marchex Reports 2025 Financial Results: Revenue Decline Amid AI Transition
- Revenue Decline: In Q4 2025, GAAP revenue was $10.8 million, down 9.2% from $11.9 million in Q4 2024, with total revenue for 2025 at $45.4 million, a 6.1% decrease from $48.1 million in 2024, indicating pressure in market competitiveness.
- Increased Net Loss: The net loss for Q4 2025 was $2.3 million, or $0.05 per share, widening from a $1.9 million loss and $0.04 per share in Q4 2024, with a total annual net loss of $5.2 million, reflecting challenges faced during the transition.
- Adjusted EBITDA Performance: Adjusted EBITDA for Q4 2025 was a loss of $1.2 million, significantly worse than the $0.4 million loss in Q4 2024, although excluding reorganization costs would yield a $0.4 million gain, indicating ongoing cost challenges during the transition.
- AI Transition Outlook: Marchex aims to accelerate revenue growth in 2026, anticipating sequential revenue increases in Q2 compared to Q1, with adjusted EBITDA potentially exceeding $500,000, showcasing confidence in leveraging AI technology for future growth.
See More
MARCHEX INC Reports Q4 Net Loss of $2.3 Million, Equivalent to $0.05 Per Diluted Share
- Financial Performance: MARCHEX INC reported a net loss of $2.3 million for Q4.
- Earnings Per Share: The loss translates to $0.05 per diluted share.
See More
MARCHEX INC Reports Q4 GAAP Revenue of $10.8 Million
- Company Overview: MARCHEX INC reported a revenue of $10.8 million for Q4, indicating its financial performance during this period.
- Financial Highlights: The revenue figure reflects the company's ongoing operations and market position within its industry.
See More
Marchex and Freshpaint Integration Enhances Healthcare Marketing Effectiveness
- Integration Enhances Marketing Effectiveness: The Marchex and Freshpaint integration enables healthcare marketers to optimize advertising spend and improve return on ad spend (ROAS) through compliant, high-fidelity data, thereby achieving stronger marketing outcomes in a complex regulatory environment.
- Data Security and Privacy Protection: Freshpaint's data platform ensures that healthcare organizations can securely connect and activate data across channels, helping them link marketing spend to patient appointment outcomes while safeguarding patient privacy and complying with industry regulations.
- Precise Patient Interaction Analysis: By combining Marchex's industry-specific conversation intelligence with Freshpaint's privacy-first infrastructure, marketers gain clearer visibility into patient interactions that shape demand, enhancing appointment volumes and patient acquisition efficiency.
- Comprehensive Marketing Capabilities: The integrated solution supports campaign optimization, audience segmentation, patient journey tracking, and attribution of marketing performance to scheduled appointments or visits, ensuring improved marketing effectiveness while adhering to healthcare privacy regulations.
See More
Marchex Q4 2025 Earnings Call Insights
- Revenue Shift: For Q4 2025, Marchex reported revenue of $10.8 million, down from $11.5 million in Q3, primarily due to migration activities; however, new sales and upsells from existing customers positively impacted the company.
- Technology Migration: The company anticipates completing the migration of approximately 1,000 customers by the end of 2025, positioning itself to focus on accelerating revenue growth and margin expansion, with a projected 10% revenue growth in 2026.
- AI-Driven Product Innovation: Marchex is leveraging AI to introduce new bundled solutions, with initial positive adoption indications in the Home Services and Auto Services sectors, highlighting the company's strategic advantage in customer acquisition and retention.
- Acquisition Outlook: The Archenia acquisition is expected to close by June 2026, with combined quarterly revenues potentially reaching $15 million and annual growth rates projected between 15% and 20%, indicating strong market potential.
See More
Marchex Reports Q4 2025 Earnings Miss with Significant Losses
- Earnings Report Disappointment: Marchex's Q4 2025 non-GAAP EPS of -$0.04 misses expectations by $0.03, indicating ongoing pressure on the company's profitability.
- Revenue Decline: The fourth quarter revenue of $10.8 million represents a 9.4% year-over-year decrease, falling short of expectations and reflecting weakened market demand and intensified competition.
- Adjusted EBITDA Loss: The adjusted EBITDA loss of $1.2 million for Q4 2025 is significantly higher than the $0.4 million loss reported in Q4 2024, highlighting challenges in cost management.
- Impact of Reorganization Costs: The 2025 adjusted EBITDA loss includes $1.6 million in reorganization and historical acquisition-related costs, but excluding these would result in a $0.4 million gain, suggesting potential profitability in core operations.
See More
Marchex Reports 2025 Financial Results: Revenue Decline Amid AI Transition
- Revenue Decline: In Q4 2025, GAAP revenue was $10.8 million, down 9.2% from $11.9 million in Q4 2024, with total revenue for 2025 at $45.4 million, a 6.1% decrease from $48.1 million in 2024, indicating pressure in market competitiveness.
- Increased Net Loss: The net loss for Q4 2025 was $2.3 million, or $0.05 per share, widening from a $1.9 million loss and $0.04 per share in Q4 2024, with a total annual net loss of $5.2 million, reflecting challenges faced during the transition.
- Adjusted EBITDA Performance: Adjusted EBITDA for Q4 2025 was a loss of $1.2 million, significantly worse than the $0.4 million loss in Q4 2024, although excluding reorganization costs would yield a $0.4 million gain, indicating ongoing cost challenges during the transition.
- AI Transition Outlook: Marchex aims to accelerate revenue growth in 2026, anticipating sequential revenue increases in Q2 compared to Q1, with adjusted EBITDA potentially exceeding $500,000, showcasing confidence in leveraging AI technology for future growth.
See More
MARCHEX INC Reports Q4 Net Loss of $2.3 Million, Equivalent to $0.05 Per Diluted Share
- Financial Performance: MARCHEX INC reported a net loss of $2.3 million for Q4.
- Earnings Per Share: The loss translates to $0.05 per diluted share.
See More
MARCHEX INC Reports Q4 GAAP Revenue of $10.8 Million
- Company Overview: MARCHEX INC reported a revenue of $10.8 million for Q4, indicating its financial performance during this period.
- Financial Highlights: The revenue figure reflects the company's ongoing operations and market position within its industry.
See More
Marchex and Freshpaint Integration Enhances Healthcare Marketing Effectiveness
- Integration Enhances Marketing Effectiveness: The Marchex and Freshpaint integration enables healthcare marketers to optimize advertising spend and improve return on ad spend (ROAS) through compliant, high-fidelity data, thereby achieving stronger marketing outcomes in a complex regulatory environment.
- Data Security and Privacy Protection: Freshpaint's data platform ensures that healthcare organizations can securely connect and activate data across channels, helping them link marketing spend to patient appointment outcomes while safeguarding patient privacy and complying with industry regulations.
- Precise Patient Interaction Analysis: By combining Marchex's industry-specific conversation intelligence with Freshpaint's privacy-first infrastructure, marketers gain clearer visibility into patient interactions that shape demand, enhancing appointment volumes and patient acquisition efficiency.
- Comprehensive Marketing Capabilities: The integrated solution supports campaign optimization, audience segmentation, patient journey tracking, and attribution of marketing performance to scheduled appointments or visits, ensuring improved marketing effectiveness while adhering to healthcare privacy regulations.
See More
